Pharmacogenomics and antidepression research
by
Yamada M.
Department of Psychiatry,
Showa University Karasuyama Hospital,
6-11-11, Kitakarasuyama,
Setagaya-ku, Tokyo, 157-8577 Japan.
Nihon Shinkei Seishin Yakurigaku Zasshi 2003 Apr;23(2):67-73

ABSTRACT

Although antidepressants have been used clinically for more than 50 years, no consensus has been reached concerning their precise molecular mechanism of action. Pharmacogenomics is a powerful tool that can be used to identify genes affected by antidepressants or by other effective therapeutic manipulations. Using this tool we have previously identified hundreds of cDNA fragments as antidepressant related genes (ADRGs). Some of these candidate genes may encode common functional molecules induced by chronic antidepressant treatment. Defining the roles of these molecules in drug-induced neural plasticity is likely to transform the course of research on the biological basis of antidepressants. Such detailed knowledge will have profound effects on the diagnosis, prevention, and treatment of depression. Novel biological approaches beyond the "monoamine hypothesis" are expected to evoke paradigm shifts in the future of antidepressant research.

CREB1
Options
21st century
Clomipramine
Nutrigenomics
Antidepressants
Transcriptomics
Pharmacogenetics
Pharmacogenomics
Antidepressants 2006
Future antidepressants
Proteomics and the CNS
Mss4 gene and antidepressants
Antidepressants and the genome
Antidepressants and the regulation of gene expression

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family